Immunotherapy of cancer stem cells in solid tumors: Initial findings and future prospective

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Conventional chemotherapies seemed to have reached a therapeutic plateau in the treatment of solid tumors and many metastatic diseases are still incurable. Events of chemo-resistance and relapses appear to be sustained by a subset of putative cancer stem cells (CSCs). New anticancer strategies need to face this new challenge exploring their efficacy against CSCs. Immunotherapy has raised enthusiasms in cancer therapy and its potential against CSCs is an intriguing field of research.Areas covered: In this work we reviewed the immunotherapy approaches directed against CSCs in solid tumors. We schematically divided adaptive immunotherapy strategies, mainly based on dendritic cell-vaccination, and strategies exploiting MHC-unrestricted effectors like natural killer cells, γδ T lymphocytes and cytokine-induced killer cells. Findings, strength and limitations of these models are discussed and compared highlighting their potential clinical relevance.Expert opinion: The important biologic role and clinical relevance of CSCs introduced a 'noble target' for immunotherapy and cancer treatments in general. Initial evidences suggest that CSCs may be susceptible to various types of immunotherapy attacks, overcoming their chemo-resistance. Investigation of important safety issues, based on shared features with 'normal' stem cells, along with intriguing synergisms with modulatory agents are open challenges for the next future and effective clinical translation.

Original languageEnglish
Pages (from-to)1259-1270
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume14
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Neoplastic Stem Cells
Stem cells
Immunotherapy
Tumors
Neoplasms
Cytokine-Induced Killer Cells
Expert Testimony
Therapeutics
Oncology
Chemotherapy
T-cells
Natural Killer Cells
Dendritic Cells
Vaccination
Stem Cells
T-Lymphocytes
Safety
Recurrence
Drug Therapy
Cytokines

Keywords

  • Cancer immunotherapy
  • Cancer stem cells
  • Cell therapy
  • Solid tumors

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Cite this

@article{6ab2a177a12243cc9f8457354314b678,
title = "Immunotherapy of cancer stem cells in solid tumors: Initial findings and future prospective",
abstract = "Introduction: Conventional chemotherapies seemed to have reached a therapeutic plateau in the treatment of solid tumors and many metastatic diseases are still incurable. Events of chemo-resistance and relapses appear to be sustained by a subset of putative cancer stem cells (CSCs). New anticancer strategies need to face this new challenge exploring their efficacy against CSCs. Immunotherapy has raised enthusiasms in cancer therapy and its potential against CSCs is an intriguing field of research.Areas covered: In this work we reviewed the immunotherapy approaches directed against CSCs in solid tumors. We schematically divided adaptive immunotherapy strategies, mainly based on dendritic cell-vaccination, and strategies exploiting MHC-unrestricted effectors like natural killer cells, γδ T lymphocytes and cytokine-induced killer cells. Findings, strength and limitations of these models are discussed and compared highlighting their potential clinical relevance.Expert opinion: The important biologic role and clinical relevance of CSCs introduced a 'noble target' for immunotherapy and cancer treatments in general. Initial evidences suggest that CSCs may be susceptible to various types of immunotherapy attacks, overcoming their chemo-resistance. Investigation of important safety issues, based on shared features with 'normal' stem cells, along with intriguing synergisms with modulatory agents are open challenges for the next future and effective clinical translation.",
keywords = "Cancer immunotherapy, Cancer stem cells, Cell therapy, Solid tumors",
author = "Loretta Gammaitoni and Valeria Leuci and Giulia Mesiano and Lidia Giraudo and Maja Todorovic and Fabrizio Carnevale-Schianca and Massimo Aglietta and Dario Sangiolo",
year = "2014",
doi = "10.1517/14712598.2014.918099",
language = "English",
volume = "14",
pages = "1259--1270",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Immunotherapy of cancer stem cells in solid tumors

T2 - Initial findings and future prospective

AU - Gammaitoni, Loretta

AU - Leuci, Valeria

AU - Mesiano, Giulia

AU - Giraudo, Lidia

AU - Todorovic, Maja

AU - Carnevale-Schianca, Fabrizio

AU - Aglietta, Massimo

AU - Sangiolo, Dario

PY - 2014

Y1 - 2014

N2 - Introduction: Conventional chemotherapies seemed to have reached a therapeutic plateau in the treatment of solid tumors and many metastatic diseases are still incurable. Events of chemo-resistance and relapses appear to be sustained by a subset of putative cancer stem cells (CSCs). New anticancer strategies need to face this new challenge exploring their efficacy against CSCs. Immunotherapy has raised enthusiasms in cancer therapy and its potential against CSCs is an intriguing field of research.Areas covered: In this work we reviewed the immunotherapy approaches directed against CSCs in solid tumors. We schematically divided adaptive immunotherapy strategies, mainly based on dendritic cell-vaccination, and strategies exploiting MHC-unrestricted effectors like natural killer cells, γδ T lymphocytes and cytokine-induced killer cells. Findings, strength and limitations of these models are discussed and compared highlighting their potential clinical relevance.Expert opinion: The important biologic role and clinical relevance of CSCs introduced a 'noble target' for immunotherapy and cancer treatments in general. Initial evidences suggest that CSCs may be susceptible to various types of immunotherapy attacks, overcoming their chemo-resistance. Investigation of important safety issues, based on shared features with 'normal' stem cells, along with intriguing synergisms with modulatory agents are open challenges for the next future and effective clinical translation.

AB - Introduction: Conventional chemotherapies seemed to have reached a therapeutic plateau in the treatment of solid tumors and many metastatic diseases are still incurable. Events of chemo-resistance and relapses appear to be sustained by a subset of putative cancer stem cells (CSCs). New anticancer strategies need to face this new challenge exploring their efficacy against CSCs. Immunotherapy has raised enthusiasms in cancer therapy and its potential against CSCs is an intriguing field of research.Areas covered: In this work we reviewed the immunotherapy approaches directed against CSCs in solid tumors. We schematically divided adaptive immunotherapy strategies, mainly based on dendritic cell-vaccination, and strategies exploiting MHC-unrestricted effectors like natural killer cells, γδ T lymphocytes and cytokine-induced killer cells. Findings, strength and limitations of these models are discussed and compared highlighting their potential clinical relevance.Expert opinion: The important biologic role and clinical relevance of CSCs introduced a 'noble target' for immunotherapy and cancer treatments in general. Initial evidences suggest that CSCs may be susceptible to various types of immunotherapy attacks, overcoming their chemo-resistance. Investigation of important safety issues, based on shared features with 'normal' stem cells, along with intriguing synergisms with modulatory agents are open challenges for the next future and effective clinical translation.

KW - Cancer immunotherapy

KW - Cancer stem cells

KW - Cell therapy

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84905814437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905814437&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.918099

DO - 10.1517/14712598.2014.918099

M3 - Article

C2 - 24835841

AN - SCOPUS:84905814437

VL - 14

SP - 1259

EP - 1270

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -